Healthcare Recap: Pfizer (NYSE:PFE) Accomplishes Takeover, Amgen Inc. (AMGN) Gets Positive Results on Obesity Drug from Monkeys

  on Nov 29,2012 Posted in Business News ,Featured
Share |
We're on   

Pfizer (NYSE:PFE) has accomplished its buyout of the privately-possessed NextWave Pharmaceuticals, a specialty pharmaceutical company that focuses upon the development and commercialization of products focused at the cure of attention deficit hyperactivity sickness.

Pfizer Inc. (NYSE:PFE) moved up +1.73% with the closing price of $24.67. The overall volume in the last trading session was 29.57 million shares. Its fifty two week range was $19.06-$26.09. The total market capitalization remained $181.63 billion.

PFE is ahead of its 52 week low with 36.58% and its last month’s price volatility remained 1.55%. Its beta coefficient was 0.71 with a target price of $27.77. PFE has institutional ownership remained 72.95%. Company’s current year earnings per share grew with 9.08% while the five years EPS growth rate was -6.12%.

An antibody found out by Amgen Inc. (NASDAQ:AMGN) researchers lowers weight and hikes glucose tolerance in monkeys, as per resulted by a study, possibly finding a new method for curing obesity and diabetes in humans.

The obese monkeys lost almost 10 percent of their body weight in the 11-week trial, as per reported by the study, which was paid for by Amgen and launched on Wednesday by the journal Science Translational Medicine.

In last trading session, Amgen, Inc. (NASDAQ:AMGN) reported the gain of +0.07% to close at $87.04 and its overall traded volume was 4.70 million shares, more than the average volume of 4.35 million.

AMGN has earnings per share of $5.59 with the net profit margin of 26.71% and operating margin of 33.60%.

On Wednesday, Abbott Laboratories (ABT) reported that its board accepted the proposed division of its pharmaceuticals unit into an independent firm and that Abbott investors would get one share of the latest firm’s common stock for each share of Abbott stock they possess.

Abbott Laboratories (NYSE:ABT) surged +0.80% and closed at $64.57 in last trading session. The overall traded volume was 4.07 million shares. Stock’s52 weeks high price was $53.00 and 52 weeks low price was $72.47.

In its share capital ABT has 1.58billion outstanding shares while 1.58billion shares have been floated in market. Company’s current year earnings per share dropped with 1.47% while the five years EPS growth rate was +21.98%.

Boston Scientific Corporation (NYSE:BSX) has now dropped about -11.23% from its record high price level, and has advanced by 6.55% for this year. It closed at $5.69, trading -0.06% below its 200 day moving average and 7.95% above its 20 day moving average. Latest close brings its distance from its 52-week low at +18.79%. The stock has a market value is $7.81 billion.

As of latest close, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are up about 394.65% for 2012 and recently topped out a 52-week high of $13.50 (Jun 27, 2012). Since then, it has retreated 31.48% but stands 590.30% above 52-week low. The shares advanced above the 200-Day SMA ($8.56) and are now sitting 6.57% above 50-day SMA. The performance measured for the month was +8.06% and weekly performance appeared at +3.58%.




Leave a Reply